On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

Overall, linvoseltamab demonstrated "high efficacy in patients with late-stage" disease, including those with high-risk features, said study investigator Sundar Jagannath, MD, from Mount Sinai ...

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...

In 2023, Dr. Sundar Jagannath, a multiple myeloma expert at the Icahn School of Medicine at Mount Sinai, told USA TODAY that thanks to advances in treatment, he can now tell a 75-year-old who is ...

If you were to meet Dr. Sundar Jagannath in a crowded room (not that we have those anymore in the COVID-19 era), you would not assume that not only is he one of the greatest myeloma docs of all time, ...

Dr. Sundar Jagannath, a multiple myeloma expert at the Icahn School of Medicine at Mount Sinai, in New York, said he can now tell a 75-year-old, newly diagnosed patient they are unlikely to die of ...

Median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) had yet to be reached after a median follow-up of 11.1 months, reported Sundar Jagannath, MD, of the ...

--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board.

Dr. Jagannath is a distinguished oncologist who is renowned for his groundbreaking contributions to the field of multiple myeloma,” said Syed Rizvi, MD, Caribou’s chief medical officer. “Dr.

Patients and Methods Three cohorts were enrolled and treated with elotuzumab (5.0, 10, or 20 mg/kg intravenously) on days 1, 8, 15, and 22 of a 28-day cycle in the first two cycles, and days 1 and 15 ...